Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 10/20 | 0.66 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.66 |
| ▸ | OPRM1 | P35372 | 9/20 | 0.66 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.66 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.66 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.66 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.66 |
| ▸ | HTR3A | P46098 | 2/20 | 0.45 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isalmadol SCHEMBL29711375 | 1.00 | SLC6A2 (0.66) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| Isalmadol SCHEMBL6437705 | 1.00 | SLC6A2 (0.66) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| SCHEMBL5155786 | 0.90 | SLC6A2 (0.66) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| SCHEMBL159543 | 0.90 | SLC6A2 (0.63) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| SCHEMBL15654221 | 0.90 | SLC6A2 (0.63) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| SCHEMBL29966428 | 0.90 | SLC6A2 (0.63) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| SCHEMBL20473750 | 0.90 | SLC6A2 (0.63) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| SCHEMBL158342 | 0.89 | SLC6A2 (0.73) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| SCHEMBL17506037 | 0.89 | OPRM1 (0.62) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| SCHEMBL19461051 | 0.89 | OPRM1 (0.62) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1127871-B1 | NEW ESTERS DERIVED FROM SUBSTITUTED PHENYL-CYCLOHEXYL COMPOUNDS | VITA LAB (ES) | 2003-09-10 | — | — | EP | claimed |
| US-20030100598-A1 | Novel esters derived from (rr,ss)-2-hydroxybenzoate of 3-(2-dimethylaminomethyl-1-hydroxycyclohexyl)phenyl | LABORATORIOS VITA, S.A. (ES) | 2003-05-29 | — | — | US | claimed |
| US-6455585-B1 | HAVE A HIGHER ANALGESIC ACTIVITY, A LOWER TOXICITY AND A LONGER EFFECTIVE TIME PERIOD THAN TRAMADOL. | VITA INVEST, S.A. (ES) | 2002-09-24 | — | — | US | claimed |
| EP-1127871-A1 | NEW ESTERS DERIVED FROM SUBSTITUTED PHENYL-CYCLOHEXYL COMPOUNDS | VITA-INVEST, S.A. (ES) | 2001-08-29 | — | — | EP | claimed |
| WO-2007059894-A2 | MULTI-CYCLIC COMPOUNDS IN PRESSURE-SENSITIVE ADHESIVES | Grünenthal GmbH (DE) | 2007-05-31 | — | — | WO | disclosed |
| US-6894076-B2 | Esters derived from (RR,SS)-2-hydroxybenzoate of 3-(2-dimethylaminomethyl-1-hydroxycyclohexyl)phenyl | VITA-INVEST, S.A. (ES) | 2005-05-17 | — | — | US | disclosed |
| US-6894076-B2 | Esters derived from (RR,SS)-2-hydroxybenzoate of 3-(2-dimethylaminomethyl-1-hydroxycyclohexyl)phenyl | VITA-INVEST, S.A. (ES) | 2005-05-17 | — | — | US | disclosed |
| EP-1251120-B1 | ESTERS DERIVED FROM (RR,SS)-2-HYDROXYBENZOATE OF 3-(2-DIMETHYLAMINOMETHYL-1-HYDROXYCYCLOHEXYL)PHENYL | VITA LAB (ES) | 2004-12-08 | — | — | EP | disclosed |
| EP-1127871-B1 | NEW ESTERS DERIVED FROM SUBSTITUTED PHENYL-CYCLOHEXYL COMPOUNDS | VITA LAB (ES) | 2003-09-10 | — | — | EP | disclosed |
| US-20030100598-A1 | Novel esters derived from (rr,ss)-2-hydroxybenzoate of 3-(2-dimethylaminomethyl-1-hydroxycyclohexyl)phenyl | LABORATORIOS VITA, S.A. (ES) | 2003-05-29 | — | — | US | disclosed |
| CN-1414946-A | Novel esters derived from (RR,SS)-2-hydroxybenzoate of 3-(2-dimethylaminomethyl-1-hydroxy cyclohexyl) phenyl | VITA INVEST SA (ES) | 2003-04-30 | — | — | CN | disclosed |
| EP-1251120-A1 | NOVEL ESTERS DERIVED FROM (RR,SS)-2-HYDROXYBENZOATE OF 3-(2-DIMETHYLAMINOMETHYL-1-HYDROXYCYCLOHEXYL)PHENYL | VITA-INVEST, S.A. (ES) | 2002-10-23 | — | — | EP | disclosed |
| EP-1251120-A1 | NOVEL ESTERS DERIVED FROM (RR,SS)-2-HYDROXYBENZOATE OF 3-(2-DIMETHYLAMINOMETHYL-1-HYDROXYCYCLOHEXYL)PHENYL | VITA-INVEST, S.A. (ES) | 2002-10-23 | — | — | EP | disclosed |
| US-6455585-B1 | HAVE A HIGHER ANALGESIC ACTIVITY, A LOWER TOXICITY AND A LONGER EFFECTIVE TIME PERIOD THAN TRAMADOL. | VITA INVEST, S.A. (ES) | 2002-09-24 | — | — | US | disclosed |
| EP-1127871-A1 | NEW ESTERS DERIVED FROM SUBSTITUTED PHENYL-CYCLOHEXYL COMPOUNDS | VITA-INVEST, S.A. (ES) | 2001-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100598-A1 | Novel esters derived from (rr,ss)-2-hydroxybenzoate of 3-(2-dimethylaminomethyl-1-hydroxycyclohexyl)phenyl | OPRK1, CYP2E1, OPRD1 | SLC6A2 1155/4885SLC6A4 576/4885OPRM1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.